Valuation: Singular Genomics Systems, Inc.

Market Cap 49.23M 43.14M 40.05M 36.8M 69.34M 4.75B 70.36M 477M 187M 2.32B 185M 181M 8.03B P/E 2022
-1.57x
P/E 2023 -0.35x
Enterprise Value -50.88M -44.58M -41.39M -38.03M -71.66M -4.91B -72.72M -493M -193M -2.4B -191M -187M -8.3B EV / Sales 2022
-56,007,684x
EV / Sales 2023 -22,792,100x
Free-Float
84.03%
Yield 2022 *
-
Yield 2023 -
3 years 5.34
Extreme 5.34
28.38
5 years 5.34
Extreme 5.34
600
10 years 5.34
Extreme 5.34
1,001.1
Manager TitleAgeSince
Chief Executive Officer - 2026-04-27
Chief Operating Officer 67 2023-08-31
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 40 2025-02-20
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
2/21/25 Issuer sale

Founder

262,242 10.3366%
2/21/25 Issuer sale

Director

6,783 0.2674%
2/21/25 Issuer sale

Director

6,907 0.2722%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-.--%-.--%-27.44% 50.7M
+0.57%-1.65%+23.11%-6.36% 196B
+0.07%-10.78%-5.67%-29.99% 126B
-2.68%-12.41%-33.33%+1.20% 120B
-0.51%-0.16%-58.35%-19.17% 63.87B
-0.21%-3.32%+10.58%-8.86% 48.58B
-1.98%-3.58%-27.13%-33.84% 43.93B
+0.45%-0.93%+14.86%+4.58% 37.69B
+0.89%-1.09%+29.00%+28.44% 36.41B
-0.86%+1.99%+87.07%+0.20% 28.88B
Average +1.11%-3.05%+4.02%-9.12% 70.13B
Weighted average by Cap. +2.55%-4.99%-0.68%-9.70%

Financials

2022 2023
Net sales 0.76 0.67 0.62 0.57 1.08 73.82 1.09 7.41 2.9 36.12 2.87 2.81 124.78 2.91 2.55 2.37 2.18 4.1 280.9 4.16 28.21 11.04 137.45 10.93 10.69 474.81
Net income -90.88M -79.63M -73.92M -67.93M -128M -8.77B -130M -881M -345M -4.29B -341M -334M -14.82B -94.82M -83.08M -77.13M -70.87M -134M -9.15B -136M -919M -360M -4.48B -356M -348M -15.47B
Net Debt -186M -163M -152M -139M -262M -17.98B -266M -1.81B -707M -8.8B -700M -684M -30.4B -100M -87.72M -81.43M -74.83M -141M -9.66B -143M -970M -380M -4.73B -376M -368M -16.33B
Logo Singular Genomics Systems, Inc.
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
Employees
255
  1. Stock Market
  2. Stocks
  3. OMIC Stock